CoChat

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma

Open access
Chen, Lindi, Rousseau, Raphaël F., Middleton, Steven A., Nichols, Gwen L., Newell, David R., Lunec, John, Tweddle, Deborah A. · 2015 · Oncotarget
Cited by 81

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

// Lindi Chen 1 , Raphaël F. Rousseau 2 , Steven A. Middleton 3 , Gwen L. Nichols 3 , David R. Newell 1 , John Lunec 1 and Deborah A. Tweddle 1 1 Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle, United Kingdom 2 Genentech Inc., South San Francisco, CA, USA 3 Hoffmann-La Roche Inc., Nutley, NJ, USA Correspondence to: Deborah A. Tweddle, email: // Keywords : neuroblastoma, MDM2-p53 antagonists, RG7388, combination therapy, Calcusyn Received : December 17, 2014 Accepted : February 17, 2015 Published : March 10, 2015 Abstract Neuroblastoma is a predominantly p53 wild-type (wt) tumour and MDM2-p53 antagonists offer a novel therapeutic strategy for neuroblastoma patients. RG7388 (Roche) is currently undergoing early phase clinical evaluation in adults. This study assessed the efficacy of RG7388 as a single-agent and in combination with chemotherapies currently used to treat neuroblastoma in a panel of neuroblastoma cell lines. RG7388 GI 50 concentrations were determined in 21 p53-wt and mutant neuroblastoma cell lines of varying MYCN , MDM2 and p14 ARF status, together with MYCN-regulatable Tet21N cells. The primary determinant of response was the presence of wt p53, and overall there was a >200-fold difference in RG7388 GI 50 concentrations for p53-wt versus mutant cell lines. Tet21N MYCN+ cells were significantly more sensitive to RG7388 compared with MYCN- cells. Using median-effect analysis in 5 p53-wt neuroblastoma cell lines, selected combinations of RG7388 with cisplatin, doxorubicin, topotecan, temozolomide and busulfan were synergistic. Furthermore, combination treatments led to increased apoptosis, as evident by higher caspase-3/7 activity compared to either agent alone. These data show that RG7388 is highly potent against p53-wt neuroblastoma cells, and strongly supports its further evaluation as a novel therapy for patients with high-risk neuroblastoma and wt p53 to potentially improve survival and/or reduce toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3504

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 81

Metadata

Authors
Chen, L., Rousseau, R. F., Middleton, S. A., Nichols, G. L., Newell, D. R., Lunec, J., & Tweddle, D. A.
Venue
Oncotarget
Published
2015-03-10
Volume
6
Issue
12
Pages
10207-10221
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1895234166
Cited by
81
References
9
FWCI
6.07
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. https://app.cochat.ai/papers/10.18632/oncotarget.3504
The paper
Chen, L., Rousseau, R. F., Middleton, S. A., Nichols, G. L., Newell, D. R., Lunec, J., & Tweddle, D. A. (2015). Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. https://doi.org/10.18632/oncotarget.3504

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.